Skip to main content
PMC home page
Pharmaceutics logoLink to Pharmaceutics
. 2023 Jan 19;15(2):342. doi: 10.3390/pharmaceutics15020342

Correction: Lee et al. The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b. Pharmaceutics 2022, 14, 1511

Yue-Zhi Lee 1,†, Hsing-Yu Hsu 1,†, Cheng-Wei Yang 1,†, Yi-Ling Lin 2, Sui-Yuan Chang 3, Ruey-Bing Yang 2, Jian-Jong Liang 2, Tai-Ling Chao 3, Chun-Che Liao 2, Han-Chieh Kao 3, Jang-Yang Chang 1, Huey-Kang Sytwu 4, Chiung-Tong Chen 1, Shiow-Ju Lee 1,*
PMCID: PMC9870069  PMID: 36840037

Changes to “authors who contributed equally”

In the original publication [1], the authors who had “contributed equally” were not listed. The corrected statement appears here. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Reference

  • 1.Lee Y.-Z., Hsu H.-Y., Yang C.-W., Lin Y.-L., Chang S.-Y., Yang R.-B., Liang J.-J., Chao T.-L., Liao C.-C., Kao H.-C., et al. The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b. Pharmaceutics. 2022;14:1511. doi: 10.3390/pharmaceutics14071511. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Pharmaceutics are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES